SMTL ID : 8bx9.2 (1 other biounit)

Crystal structure of JAK2 JH1 in complex with ilginatinib

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 1.40 Å

Oligo State

monomer

Ligands

1 x S59: Ilginatinib(Non-covalent)

S59.1: 20 residues within 4Å: Chain A: L.39, G.40, V.47, A.64, V.95, M.113, E.114, Y.115, L.116, P.117, Y.118, G.119, S.120, R.164, N.165, I.166, L.167, G.177, D.178 Ligands: DMS.2 9 PLIP interactions: 9 interactions with chain A Hydrophobic interactions: A:L.39, A:L.39, A:V.47, A:Y.115, A:L.167, A:L.167 Hydrogen bonds: A:L.39, A:L.116, A:L.116

1 x DMS: DIMETHYL SULFOXIDE(Non-functional Binders)

DMS.2: 6 residues within 4Å: Chain A: G.42, N.43, R.164, N.165, D.178 Ligands: S59.1 1 PLIP interactions: 1 interactions with chain A Water bridges: A:D.178

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Miao, Y. et al., Structural basis for JAK2 inhibition by clinical stage inhibitors. To Be Published

Release Date

2023-12-20

Peptides

Tyrosine-protein kinase JAK2: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
B

Tyrosine-protein kinase JAK2

Related Entries With Identical Sequence